On Monday, Verona Pharma Plc ADR (NASDAQ: VRNA) opened lower -3.82% from the last session, before settling in for the closing price of $46.59. Price fluctuations for VRNA have ranged from $11.39 to $48.96 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -49.71% annually for the last half of the decade. Company’s average yearly earnings per share was noted -200.00% at the time writing. With a float of $68.91 million, this company’s outstanding shares have now reached $81.83 million.
In an organization with 79 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 80.41%, operating margin of -2370.63%, and the pretax margin is -2352.52%.
Verona Pharma Plc ADR (VRNA) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Verona Pharma Plc ADR is 15.79%, while institutional ownership is 67.30%. The most recent insider transaction that took place on Dec 05 ’24, was worth 3,205,226. In this transaction President and CEO of this company sold 640,264 shares at a rate of $5.01, taking the stock ownership to the 14,367,552 shares. Before that another transaction happened on Dec 06 ’24, when Company’s President and CEO sold 162,800 for $5.01, making the entire transaction worth $815,400. This insider now owns 14,204,752 shares in total.
Verona Pharma Plc ADR (VRNA) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -200.00% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Check out the current performance indicators for Verona Pharma Plc ADR (VRNA). In the past quarter, the stock posted a quick ratio of 13.03. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 645.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.94, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach -0.12 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Let’s dig in a bit further. During the last 5-days, its volume was 1.26 million. That was inferior than the volume of 1.51 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 68.36%. Additionally, its Average True Range was 2.05.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 83.03%, which indicates a significant increase from 55.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.47% in the past 14 days, which was higher than the 44.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $39.72, while its 200-day Moving Average is $25.67. However, in the short run, Verona Pharma Plc ADR’s stock first resistance to watch stands at $46.03. Second resistance stands at $47.24. The third major resistance level sits at $47.95. If the price goes on to break the first support level at $44.11, it is likely to go to the next support level at $43.40. Assuming the price breaks the second support level, the third support level stands at $42.19.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
There are currently 80,440K shares outstanding in the company with a market cap of 3.67 billion. Presently, the company’s annual sales total 0 K according to its annual income of -54,370 K. Last quarter, the company’s sales amounted to 5,620 K and its income totaled -42,960 K.
